SCHEDULE: Caligan Partners Exits Y-mAbs Therapeutics Stake
Beneficial Ownership Amendment (Schedule 13G)
Caligan Partners LP and David Johnson have reported a complete divestment of their beneficial ownership in Y-mAbs Therapeutics, Inc., now holding 0% of the common stock.
Summary
- Caligan Partners LP and David Johnson, previously beneficial owners, have fully divested their stake in Y-mAbs Therapeutics, Inc.
- As of September 30, 2025, the reporting persons hold 0.00 shares, representing 0% of the common stock.
- This filing is an Amendment No. 1 to a Schedule 13G, indicating a change from a previously reported beneficial ownership position.
- Caligan Partners LP serves as an investment manager, and David Johnson is its Managing Partner.
Sentiment
Score: 3
Explanation: The sentiment is moderately negative due to the complete divestment of shares by an institutional investor, which typically signals a loss of confidence or a strategic decision to exit the position.
Negatives
- The complete divestment by an institutional investor like Caligan Partners LP could be perceived as a negative signal regarding the company's future prospects or current valuation.
Future Outlook
NA
Industry Context
This filing reflects a specific institutional investor's portfolio reallocation or change in investment thesis regarding Y-mAbs Therapeutics, Inc. It does not provide broader industry trends but indicates a shift in investor sentiment from a notable fund.
Stakeholder Impact
- Shareholders may perceive the complete exit of an institutional investor as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 09/30/2025 | Date of the event which required the filing of this statement (complete divestment of shares). |
| 11/14/2025 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Recommendation
holdWhile a complete divestment by an institutional investor is a negative signal, a 'hold' recommendation is appropriate without further information on Y-mAbs Therapeutics' fundamentals or other market-moving news. Investors should consider this divestment as a data point indicating a significant investor's lack of conviction or reallocation of capital, prompting further due diligence into the company's performance and outlook.
Keywords
Y-mAbs Therapeutics, Caligan Partners, David Johnson, Beneficial Ownership, Divestment, Institutional Investor, Common Stock, SEC Filing, Schedule 13G
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.